| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Agustín Falco, Mariano Leiva, Albano Blanco, Guido Cefarelli, Andrés Rodriguez, Juan Melo, Federico Cayol, Manglio Miguel Rizzo, Alejandro Sola, Hernán Rodríguez Montani, Matías Chacon, Diego Enrico and Federico Waisberg |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Agustín Falco, MD, Staff Physician, Department of Medical Oncology, Head and Neck Unit, Alexander Fleming Cancer Institute, Cramer 1180, Buenos Aires 1428, Argentina. afalco@alexanderfleming.org |
| Key Words |
Recurrent and/or metastatic head and neck cancer; TPEx schema; Cetuximab; Docetaxel; Cisplatin; First-line |
| Core Tip |
We evaluated the safety and efficacy of the combination platinum, taxanes, and cetuximab scheme as a first-line therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck in a real-world setting. Among the 24 patients included, the median progression-free survival was 6.9 mo (95% confidence interval: 6.5-7.3), and the overall survival rate at 12 mo was 82.4%, which was consistent with previous clinical trials. Patients with documented tumor response showed statistically better progression-free survival than those with disease stabilization or progression (P = 0.034). The combination platinum, taxanes, and cetuximab regimen was adequately tolerated by most of the analyzed patients, as the incidence of grade 3-4 adverse events was surprisingly lower than expected (25%). |
| Publish Date |
2022-02-23 09:24 |
| Citation |
Falco A, Leiva M, Blanco A, Cefarelli G, Rodriguez A, Melo J, Cayol F, Rizzo MM, Sola A, Rodríguez Montani H, Chacon M, Enrico D, Waisberg F. First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study. World J Clin Oncol 2022; 13(2): 147-158 |
| URL |
https://www.wjgnet.com/2218-4333/full/v13/i2/147.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v13.i2.147 |
